EIF5A2 and cancer: For example, downregulation of ATXN3 promotes sensitivity of neuroblastoma cells to Perifosine and MK-2206, but reduces sensitivity to etoposide and cisplatin in these cells (Gong et al., 2021); ATXN3 enhances breast cancer (BRCA) metastasis by deubiquitinating KLF4 (Zou et al., 2019); ATXN3 promotes mRNA expression of EIF5A2 by stabilizing EIF5A2 to decrease its ubiquitination and degradation in anaplastic thyroid carcinoma (Zhuang et al., 2021).